By law, smokers with severe tobacco dependence are entitled to receive one-off drug therapy for smoking cessation as part of evidence-based programmes reimbursed by the German statutory health insurance (SHI).
FDA Panel Reluctantly Backs Patisiran for ATTR Cardiomyopathy
FDA advisors conceded on Wednesday that the benefit-risk balance of patisiran (Onpattro) technically checks out in wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, also known
September 14, 2023